OMEROS CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OMEROS CORP (OMER) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.62M, a 21.50% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.89M, a 22.99% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.94M, a 26.51% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.06M, a 25.40% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.19M, a 21.93% decline from fiscal 2024.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.49M, a 9.93% decline from fiscal 2023.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.65M, a 17.21% decline from fiscal 2022.
- OMEROS CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.07M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.62M 10-Q · filed 2026-08-12 | $3.51M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $1.89M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $8.19M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.94M 10-Q · filed 2025-11-13 | $4.01M derived: sum of 2 quarters · filed 2026-08-12 | $6.46M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $2.06M 10-Q · filed 2026-08-12 | $4.52M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $2.45M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $10.49M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $2.64M 10-Q · filed 2025-11-13 | $5.41M derived: sum of 2 quarters · filed 2025-11-13 | $8.07M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $2.77M 10-Q · filed 2025-11-13 | $5.43M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $2.66M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $11.65M 10-K · filed 2026-03-31 | |||
| 2023-03-31 | $2.95M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $14.07M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |